IL-17-Producing Cells in Tumor Immunity: Friends or Foes?

키워드

참고문헌 (145)

1. Pelletier M, "Evidence for a cross-talk between human neutrophils and Th17 cells", Blood, 115, pp.335~343 (2010)
2. Mangan PR, "Transforming growth factor-β induces development of the TH17 lineage", Nature, 441, pp.231~234 (2006)
3. Chung Y, "Critical regulation of early Th17 cell differentiation by interleukin-1 signaling", Immunity, 30, pp.576~587 (2009)
4. McGeachy MJ, "The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo", Nat Immunol, 10, pp.314~324 (2009)
5. Ivanov II, "The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells", Cell, 126, pp.1121~1133 (2006)
6. Chung Y, "Expression and regulation of IL-22 in the IL-17-producing CD4+ T lymphocytes", Cell Res, 16, pp.902~907 (2006)
7. Yang XO, "Regulation of inflammatory responses by IL-17F", J Exp Med, 205, pp.1063~1075 (2008)
8. El-Behi M, "The encephalitogenicity of TH17 cells is dependent on IL-1-and IL-23-induced production of the cytokine GM-CSF", Nat Immunol, 12, pp.568~575 (2011)
9. Codarri L, "RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation", Nat Immunol, 12, pp.560~567 (2011)
10. 김병석, "Targeting IL-17 in autoimmunity and inflammation", Archives of Pharmacal Research, 39(11), pp.1537~1547 (2016), 대한약학회
11. Zhong W, "Rituximab or irradiation promotes IL-17 secretion and thereby induces resistance to rituximab or irradiation", Cell Mol Immunol, 14, pp.1020~1022 (2017)
12. Muranski P, "Tumor-specific Th17-polarized cells eradicate large established melanoma", Blood, 112, pp.362~373 (2008)
13. Kryczek I, "Endogenous IL-17 contributes to reduced tumor growth and metastasis", Blood, 114, pp.357~359 (2009)
14. Sethi V, "Gut microbiota promotes tumor growth in mice by modulating immune response", Gastroenterology, 155, pp.33~37 (2018)
15. Kuang DM, "Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients", J Immunol, 185, pp.1544~1549 (2010)
16. Du JW, "Interleukin-17, produced by lymphocytes, promotes tumor growth and angiogenesis in a mouse model of breast cancer", Mol Med Rep, 6, pp.1099~1102 (2012)
17. Irshad S, "RORγt+ Innate Lymphoid Cells Promote Lymph Node Metastasis of Breast Cancers", Cancer Res, 77, pp.1083~1096 (2017)
18. Rei M, "Murine CD27(-)Vγ6(+)γδ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages", Proc Natl Acad Sci U S A, 111, pp.E3562~ (2014)
19. Charles KA, "The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans", J Clin Invest, 119, pp.3011~3023 (2009)
20. Cheng M, "Microbiota modulate tumoral immune surveillance in lung through a γδT17 immune cell-dependent mechanism", Cancer Res, 74, pp.4030~4041 (2014)
21. Calcinotto A, "Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression", Nat Commun, 9, pp.4832~ (2018)
22. Coffelt SB, "IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis", Nature, 522, pp.345~348 (2015)
23. Chang SH, "T helper 17 cells play a critical pathogenic role in lung cancer", Proc Natl Acad Sci U S A, 111, pp.5664~5669 (2014)
24. Jin C, "Commensal microbiota promote lung cancer development via γδ T cells", Cell, 176, pp.998~1013 (2019)
25. You R, "IL17A regulates tumor latency and metastasis in lung adeno and squamous SQ. 2b and AD. 1 cancer", Cancer Immunol Res, 6, pp.645~657 (2018)
26. Wang L, "IL-17 enhances tumor development in carcinogen-induced skin cancer", Cancer Res, 70, pp.10112~10120 (2010)
27. Chan KS, "Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis", J Clin Invest, 114, pp.720~728 (2004)
28. Housseau F, "Redundant innate and adaptive sources of IL17 production drive colon tumorigenesis", Cancer Res, 76, pp.2115~2124 (2016)
29. Kryczek I, "IL-22+CD4+ T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L", Immunity, 40, pp.772~784 (2014)
30. Wang K, "Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis", Immunity, 41, pp.1052~1063 (2014)
31. Kirchberger S, "Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model", J Exp Med, 210, pp.917~931 (2013)
32. Abousamra NK, "Prognostic value of Th17 cells in acute leukemia", Med Oncol, 30, pp.732~ (2013)
33. Han Y, "Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia", Cancer Sci, 105, pp.933~942 (2014)
34. Chen WC, "Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor", Histopathology, 63, pp.225~233 (2013)
35. Faucheux L, "A multivariate Th17 metagene for prognostic stratification in T cell non-inflamed triple negative breast cancer", OncoImmunology, 8, pp.e1624130~ (2019)
36. Liu J, "IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma", Biochem Biophys Res Commun, 407, pp.348~354 (2011)
37. Tosolini M, "Clinical impact of different classes of infiltrating T cytotoxic and helper cells(Th1, th2, treg, th17)in patients with colorectal cancer", Cancer Res, 71, pp.1263~1271 (2011)
38. Chen J, "The effect of immune microenvironment on the progression and prognosis of colorectal cancer", Med Oncol, 31, pp.82~ (2014)
39. Alves JJ, "Th17 response in patients with cervical cancer", Oncol Lett, 16, pp.6215~6227 (2018)
40. Punt S, "Angels and demons : Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer", Oncoimmunology, 4, pp.e984539~ (2015)
41. Wang B, "Mast cells expressing interleukin 17 in the muscularis propria predict a favorable prognosis in esophageal squamous cell carcinoma", Cancer Immunol Immunother, 62, pp.1575~1585 (2013)
42. Lv L, "The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma", PLoS One, 6, pp.e18219~ (2011)
43. Zhang B, "The prevalence of Th17 cells in patients with gastric cancer", Biochem Biophys Res Commun, 374, pp.533~537 (2008)
44. Yamada Y, "Prevalence and clinical relevance of Th17 cells in patients with gastric cancer", J Surg Res, 178, pp.685~691 (2012)
45. Zhang JP, "Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients", J Hepatol, 50, pp.980~989 (2009)
46. Liao R, "High expression of IL-17 and IL-17RE associate with poor prognosis of hepatocellular carcinoma", J Exp Clin Cancer Res, 32, pp.3~ (2013)
47. Yan J, "Prevalence and clinical relevance of T-helper cells, Th17 and Th1, in hepatitis B virus-related hepatocellular carcinoma", PLoS One, 9, pp.e96080~ (2014)
48. Ye ZJ, "Generation and differentiation of IL-17-producing CD4+ T cells in malignant pleural effusion", J Immunol, 185, pp.6348~6354 (2010)
49. Gong Y, "Cell origins and significance of IL-17 in malignant pleural effusion", Clin Transl Oncol, 16, pp.807~813 (2014)
50. Bao Z, "IL-17A-producing T cells are associated with the progression of lung adenocarcinoma", Oncol Rep, 36, pp.641~650 (2016)
51. Zelba H, "Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by Melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma", Clin Cancer Res, 20, pp.4390~4399 (2014)
52. Dhodapkar KM, "Dendritic cells mediate the induction of polyfunctional human IL17-producing cells(Th17-1 cells)enriched in the bone marrow of patients with myeloma", Blood, 112, pp.2878~2885 (2008)
53. Shen CJ, "Increased numbers of T helper 17 cells and the correlation with clinicopathological characteristics in multiple myeloma", J Int Med Res, 40, pp.556~564 (2012)
54. Zhang YL, "Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways", Mol Cancer, 9, pp.4~ (2010)
55. Li J, "Tumor microenvironment macrophage inhibitory factor directs the accumulation of interleukin-17-producing tumor-infiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients", J Biol Chem, 287, pp.35484~35495 (2012)
56. Xu C, "Elevated pleural effusion IL-17 is a diagnostic marker and outcome predictor in lung cancer patients", Eur J Med Res, 19, pp.23~ (2014)
57. Chen X, "Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients", Lung Cancer, 69, pp.348~354 (2010)
58. Miyahara Y, "Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer", Proc Natl Acad Sci U S A, 105, pp.15505~15510 (2008)
59. Kryczek I, "Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments", Blood, 114, pp.1141~1149 (2009)
60. He S, "Distribution and clinical significance of Th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients", Int J Mol Sci, 12, pp.7424~7437 (2011)
61. Sfanos KS, "Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing", Clin Cancer Res, 14, pp.3254~3261 (2008)
62. Derhovanessian E, "Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients", Int J Cancer, 125, pp.1372~1379 (2009)
63. Huang Y, "Clonal architectures predict clinical outcome in clear cell renal cell carcinoma", Nat Commun, 10, pp.1245~ (2019)
64. Koyama K, "Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage", Clin Cancer Res, 14, pp.6770~6779 (2008)
65. Su X, "Tumor microenvironments direct the recruitment and expansion of human Th17 cells", J Immunol, 184, pp.1630~1641 (2010)
66. Chen D, "Chemokine", chemokine receptor interactions contribute to the accumulation of Th17 cells in patients with esophageal squamous cell carcinoma, 2012, pp.73, 1068~1072
67. Yu Q, "Preferential recruitment of Th17 cells to cervical cancer via CCR6-CCL20 pathway", PLoS One, 10, pp.e0120855~ (2015)
68. Pan B, "Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3", GIV signaling pathway in non-small-cell lung cancer, 2015, pp.5, 16053~
69. Li J, "Distribution, characterization, and induction of CD8+ regulatory T cells and IL-17-producing CD8+ T cells in nasopharyngeal carcinoma", J Transl Med, 9, pp.189~ (2011)
70. Zhuang Y, "CD8+ T cells that produce interleukin-17 regulate myeloid-derived suppressor cells and are associated with survival time of patients with gastric cancer", Gastroenterology, 143, pp.951~962 (2012)
71. Lee MH, "Interleukin 17 and peripheral IL-17-expressing T cells are negatively correlated with the overall survival of head and neck cancer patients", Oncotarget, 9, pp.9825~9837 (2018)
72. Hinrichs CS, "Type 17 CD8+ T cells display enhanced antitumor immunity", Blood, 114, pp.596~599 (2009)
73. Tajima M, "IL-17", IFN-γ double producing CD8+ T(Tc17, Int Immunol, pp.2011, 23[DOI]
74. Muranski P, "Th17 cells are long lived and retain a stem cell-like molecular signature", Immunity, 35, pp.972~985 (2011)
75. Yu Y, "Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms", J Immunol, 190, pp.1873~1881 (2013)
76. Bowers JS, "Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion", JCI Insight, 2, pp.e90772~ (2017)
77. Hu X, "In vitro priming of adoptively transferred T cells with a RORγ agonist confers durable memory and stemness in vivo", Cancer Res, 78, pp.3888~3898 (2018)
78. Wu P, "γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer", Immunity, 40, pp.785~800 (2014)
79. Daley D, "γδ T cells support pancreatic oncogenesis by restraining αβ T cell activation", Cell, 166, pp.1485~1499 (2016)
80. 권동일, "Lineage Differentiation Program of Invariant Natural Killer T Cells", Immune Network, 17(6), pp.365~377 (2017), 대한면역학회[DOI]
81. Crosby CM, "Tissue-specific functions of invariant natural killer T cells", Nat Rev Immunol, 18, pp.559~574 (2018)
82. Chang H. Kim, "Control of Innate and Adaptive Lymphocytes by the RAR-Retinoic Acid Axis", Immune Network, 18(1), pp.1~13 (2018), 대한면역학회[DOI]
83. Bruchard M, "Deciphering the roles of innate lymphoid cells in cancer", Front Immunol, 10, pp.656~ (2019)
84. Koh J, "IL23-producing human lung cancer cells promote tumor growth via conversion of innate lymphoid cell 1(ILC1)into ILC3", Clin Cancer Res, 25, pp.4026~4037 (2019)
85. Zhu X, "IL-17 expression by breast-cancer-associated macrophages : IL-17 promotes invasiveness of breast cancer cell lines", Breast Cancer Res, 10, pp.R95~ (2008)
86. Vykhovanets EV, "IL-17 Expression by macrophages is associated with proliferative inflammatory atrophy lesions in prostate cancer patients", Int J Clin Exp Pathol, 4, pp.552~565 (2011)
87. Chen X, "IL-17 producing mast cells promote the expansion of myeloid-derived suppressor cells in a mouse allergy model of colorectal cancer", Oncotarget, 6, pp.32966~32979 (2015)
88. Tu JF, "Mast cells comprise the major of interleukin 17-producing cells and predict a poor prognosis in hepatocellular carcinoma", Medicine(Baltimore), 95, pp.e3220~ (2016)
89. Liu X, "Intratumor IL-17-positive mast cells are the major source of the IL-17 that is predictive of survival in gastric cancer patients", PLoS One, 9, pp.e106834~ (2014)
90. Spolski R, "Interleukin-21 : basic biology and implications for cancer and autoimmunity", Annu Rev Immunol, 26, pp.57~79 (2008)
91. Petrella TM, "Interleukin-21 has activity in patients with metastatic melanoma : a phase II study", J Clin Oncol, 30, pp.3396~3401 (2012)
92. Petrella TM, "Final efficacy results of NCIC CTG IND. 202 : a randomized phase II study of recombinant interleukin-21(rIL21)in patients with recurrent or metastatic melanoma(MM)", J Clin Oncol, 31, pp.9032~ (2013)
93. Chapuis AG, "Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient", J Exp Med, 213, pp.1133~1139 (2016)
94. Duhen T, "Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells", Nat Immunol, 10, pp.857~863 (2009)
95. 진미림, "From Bench to Clinic: the Potential of Therapeutic Targeting of the IL-22 Signaling Pathway in Atopic Dermatitis", Immune Network, 18(6), pp.1~11 (2018), 대한면역학회[DOI]
96. Nardinocchi L, "Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer", Eur J Immunol, 45, pp.922~931 (2015)
97. Eyerich K, "IL-17 and IL-22 in immunity : driving protection and pathology", Eur J Immunol, 47, pp.607~614 (2017)
98. Jiang R, "IL-22 is related to development of human colon cancer by activation of STAT3", BMC Cancer, 13, pp.59~ (2013)
99. Lim C, "The role of the IL-22", IL-22R1 axis in cancer, 2014, pp.25, 257~271
100. Wen Z, "High expression of interleukin-22 and its receptor predicts poor prognosis in pancreatic ductal adenocarcinoma", Ann Surg Oncol, 21, pp.125~132 (2014)
101. Zhang W, "Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts", Clin Cancer Res, 14, pp.6432~6439 (2008)
102. Pylayeva-Gupta Y, "Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia", Cancer Cell, 21, pp.836~847 (2012)
103. Bayne LJ, "Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer", Cancer Cell, 21, pp.822~835 (2012)
104. Su S, "A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis", Cancer Cell, 25, pp.605~620 (2014)
105. Chen Y, "An epithelial-to-mesenchymal transition-inducing potential of granulocyte macrophage colony-stimulating factor in colon cancer", Sci Rep, 7, pp.8265~ (2017)
106. Martin-Orozco N, "T helper 17 cells promote cytotoxic T cell activation in tumor immunity", Immunity, 31, pp.787~798 (2009)
107. Ankathatti Munegowda M, "Th17 and Th17-stimulated CD8+ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity", Cancer Immunol Immunother, 60, pp.1473~1484 (2011)
108. Qian X, "Increased Th17 cells in the tumor microenvironment is mediated by IL-23 via tumor-secreted prostaglandin E2", J Immunol, 190, pp.5894~5902 (2013)
109. Numasaki M, "IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis", J Immunol, 175, pp.6177~6189 (2005)
110. Lee JW, "Differential regulation of chemokines by IL-17 in colonic epithelial cells", J Immunol, 181, pp.6536~6545 (2008)
111. 김창한, "Gut Microbiota-Derived Short-Chain Fatty Acids, T Cells, and Inflammation", Immune Network, 14(6), pp.277~288 (2014), 대한면역학회
112. Wu S, "A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses", Nat Med, 15, pp.1016~1022 (2009)
113. Grivennikov SI, "Adenoma-linked barrier defects and microbial products drive IL-23", IL-17-mediated tumour growth, 2012, pp.491, 254~258
114. Chan IH, "Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells", Mucosal Immunol, 7, pp.842~856 (2014)
115. Bagheri N, "The biological functions of IL-17 in different clinical expressions of Helicobacter pylori-infection", Microb Pathog, 81, pp.33~38 (2015)
116. McAllister F, "Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia", Cancer Cell, 25, pp.621~637 (2014)
117. Li Q, "Inhaled IL-10 suppresses lung tumorigenesis via abrogation of inflammatory macrophage-Th17 cell axis", J Immunol, 201, pp.2842~2850 (2018)
118. Wang L, "IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway", J Exp Med, 206, pp.1457~1464 (2009)
119. Chen X, "IL-17R-EGFR axis links wound healing to tumorigenesis in Lrig1+ stem cells", J Exp Med, 216, pp.195~214 (2019)
120. Fanok MH, "Role of dysregulated cytokine signaling and bacterial triggers in the pathogenesis of cutaneous T-cell lymphoma", J Invest Dermatol, 138, pp.1116~1125 (2018)
121. Haudenschild D, "Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer", J Biol Chem, 277, pp.4309~4316 (2002)
122. Steiner GE, "Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate", Prostate, 56, pp.171~182 (2003)
123. Yu H, "Crosstalk between cancer and immune cells : role of STAT3 in the tumour microenvironment", Nat Rev Immunol, 7, pp.41~51 (2007)
124. Li J, "Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression", PLoS One, 6, pp.e21816~ (2011)
125. Yang B, "The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis", Mediators Inflamm, 2014, pp.623759~ (2014)
126. Xiang T, "Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer", Oncogene, 34, pp.165~176 (2015)
127. Zhang Q, "Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition", Oncogene, 36, pp.687~699 (2017)
128. Corcoran RB, "STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis", Cancer Res, 71, pp.5020~5029 (2011)
129. Ho PL, "Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer", Cancer Res, 72, pp.3135~3142 (2012)
130. Punt S, "The correlations between IL-17 vs. Th17 cells and cancer patient survival : a systematic review", OncoImmunology, 4, pp.e984547~ (2015)
131. 박영준, "Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance", Experimental and Molecular Medicine, 50, pp.1~13 (2018), 생화학분자생물학회
132. Cochaud S, "IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1", 2, 2013, pp.3, 3456~
133. Sui G, "Interleukin-17 promotes the development of cisplatin resistance in colorectal cancer", Oncol Lett, 17, pp.944~950 (2019)
134. Chung AS, "An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy", Nat Med, 19, pp.1114~1123 (2013)
135. Nuñez S, "T helper type 17 cells contribute to anti-tumour immunity and promote the recruitment of T helper type 1 cells to the tumour", Immunology, 139, pp.61~71 (2013)
136. Majchrzak K, "Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic", Cancer Immunol Immunother, 65, pp.247~259 (2016)
137. Liu J, "Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing", Front Immunol, 10, pp.456~ (2019)
138. Cheng J, "Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies", Front Oncol, 9, pp.1237~ (2019)
139. Chung Y, "An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity", Blood, 110, pp.2013~2019 (2007)
140. 민보경, "Optimization of Large-Scale Expansion and Cryopreservation of Human Natural Killer Cells for Anti-Tumor Therapy", Immune Network, 18(4), pp.1~13 (2018), 대한면역학회[DOI]
141. Mahalingam D, "Phase 1 open-label, multicenter study of first-in-class RORγ agonist LYC-55716(cintirorgon) : safety, tolerability, and preliminary evidence of antitumor activity", Clin Cancer Res, 25, pp.3508~3516 (2019)
142. Bie Q, "Non-tumor tissue derived interleukin-17B activates IL-17RB", AKT, Sci Rep, pp.2016, 6[DOI]
143. Majchrzak K, "β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity", JCI Insight, 2, pp.90547~ (2017)
144. Guedan S, "ICOS-based chimeric antigen receptors program bipolar TH17", TH1 cells, 2014, pp.124, 1070~1080
145. 이명미, "Cytokine Signaling in Tumor Progression", Immune Network, 17(4), pp.214~227 (2017), 대한면역학회[DOI]

관련 논문AI추천